top of page
  • Recruiting
    • Jun 9, 2021

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM

Updated: May 23, 2022

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma


metformin

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma


The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma.


The names of the study drug involved in this study is:

Metformin, extended release

Placebo (a pill that has no active ingredients)


Sponsor:

Dana-Farber Cancer Institute


Collaborator:

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT04850846